-
Podocyte-targeted therapies — progress and future directions Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-05-09 Kristin Meliambro, John C. He, Kirk N. Campbell
-
Spatial transcriptomics in health and disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-05-08 Sanjay Jain, Michael T. Eadon
-
A patient perspective on kidney disease in the public health agenda Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-05-07 Daniel Gallego
Chronic kidney disease is a life-changing diagnosis for millions of people worldwide, as the risk of disease progression and kidney failure creates unbearable uncertainty and limits lifestyle. The devastating impact of advanced kidney disease must be acknowledged in the public health agenda to pave way for improved outcomes for patients at all stages of disease.
-
Role of the gut microbiota in the pathogenesis of IgA nephropathy Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-29 Ellen F. Carney
The microbiome can modulate immune responses and has an important effect on human health, but its potential causal role in acquired autoimmune diseases remains to be determined. Now, James Gleeson, Renato Monteiro and colleagues report a mechanism by which gut microbial dysbiosis could contribute to the pathogenesis of IgA nephropathy (IgAN). As the mucin layer on the luminal side of the gut wall contains
-
Progression and outcomes of rare kidney diseases Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-26 Susan J. Allison
To describe kidney and patient outcomes for individuals with rare diseases in the UK, Gale and colleagues analysed data from 27,285 patients with 28 different types of rare kidney disease in RaDaR. Over a median follow-up of 9.6 years, RaDaR participants had a significantly higher 5-year cumulative incidence of kidney failure than that of 2.81 million patients with all-cause CKD (28% versus 1%; P < 0
-
Applications of SGLT2 inhibitors beyond glycaemic control Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-26 Daniel V. O’Hara, Carolyn S. P. Lam, John J. V. McMurray, Tae Won Yi, Samantha Hocking, Jessica Dawson, Smriti Raichand, Andrzej S. Januszewski, Meg J. Jardine
-
Post-translational modifications in kidney diseases and associated cardiovascular risk Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-25 Heidi Noels, Vera Jankowski, Stefan J. Schunk, Raymond Vanholder, Sahir Kalim, Joachim Jankowski
-
Not every organ ticks the same Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-24 Khaoula Talbi, Anette Melk
-
Immune mechanisms in the pathophysiology of hypertension Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-24 Bianca A. Nguyen, Matthew R. Alexander, David G. Harrison
-
Considerations of sex as a binary variable in clinical algorithms Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-23 Dinushika Mohottige, Samira Farouk, Tonia Poteat, Asa Radix, Selma Feldman Witchel
Clinical algorithms that are used to guide medical decision-making often include sex as a variable. However, binary considerations of sex and/or gender might introduce bias due to potentially inaccurate assumptions about sex and gender-specific physiology, hormones and exposures. An equity-focused approach to sex and gender is essential when using clinical algorithms to ensure health equity across
-
Calcium signalling and transport in the kidney Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-19 Alexander Staruschenko, R. Todd Alexander, Michael J. Caplan, Daria V. Ilatovskaya
-
Thiazides in kidney transplant recipients: skin in the game Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-17 Steven Van Laecke
-
Epithelial cell states associated with kidney and allograft injury Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-17 Christian Hinze, Svjetlana Lovric, Philip F. Halloran, Jonathan Barasch, Kai M. Schmidt-Ott
-
Kidney disease: a global health priority Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-03
The prevalence of kidney disease and its associated morbidity and mortality continue to rise. This crisis cannot be tackled unless kidney disease is made a global public health priority.
-
A new era in the science and care of kidney diseases Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-04 Carmine Zoccali, Francesca Mallamaci, Liz Lightstone, Vivek Jha, Carol Pollock, Katherine Tuttle, Peter Kotanko, Andrzej Wiecek, Hans Joachim Anders, Giuseppe Remuzzi, Kamyar Kalantar-Zadeh, Adeera Levin, Raymond Vanholder
Notable progress in basic, translational and clinical nephrology research has been made over the past five decades. Nonetheless, many challenges remain, including obstacles to the early detection of kidney disease, disparities in access to care and variability in responses to existing and emerging therapies. Innovations in drug development, research technologies, tissue engineering and regenerative
-
Combination therapy for kidney disease in people with diabetes mellitus Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-03 Daniël H. van Raalte, Petter Bjornstad, David Z. I. Cherney, Ian H. de Boer, Paola Fioretto, Daniel Gordin, Frederik Persson, Sylvia E. Rosas, Peter Rossing, Jennifer A. Schaub, Katherine Tuttle, Sushrut S. Waikar, Hiddo J. L. Heerspink
Diabetic kidney disease (DKD), defined as co-existing diabetes and chronic kidney disease in the absence of other clear causes of kidney injury, occurs in approximately 20–40% of patients with diabetes mellitus. As the global prevalence of diabetes has increased, DKD has become highly prevalent and a leading cause of kidney failure, accelerated cardiovascular disease, premature mortality and global
-
Chronic kidney disease and the global public health agenda: an international consensus Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-03 Anna Francis, Meera N. Harhay, Albert C. M. Ong, Sri Lekha Tummalapalli, Alberto Ortiz, Agnes B. Fogo, Danilo Fliser, Prabir Roy-Chaudhury, Monica Fontana, Masaomi Nangaku, Christoph Wanner, Charu Malik, Anne Hradsky, Dwomoa Adu, Sunita Bavanandan, Ana Cusumano, Laura Sola, Ifeoma Ulasi, Vivekanand Jha
Early detection is a key strategy to prevent kidney disease, its progression and related complications, but numerous studies show that awareness of kidney disease at the population level is low. Therefore, increasing knowledge and implementing sustainable solutions for early detection of kidney disease are public health priorities. Economic and epidemiological data underscore why kidney disease should
-
The global landscape of kidney registries: immense challenges and unique opportunities Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-04-02 Christopher H. Grant, Fergus J. Caskey, M. Razeen Davids, Manisha Sahay, Aminu K. Bello, Dorothea Nitsch, Samira Bell
Kidney registries are essential to understanding the burden of kidney disease and facilitating the development of sustainable and effective programs for kidney disease prevention and care. Key barriers to implementation of registries at a global scale include funding and data quality. These issues warrant the attention of the global nephrology community.
-
Sex differences in kidney metabolism and DKD Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-28 Ellen F. Carney
The epidemiology of diabetic kidney disease (DKD) differs by sex, with a greater risk of kidney failure in men. New data suggest that sex differences in kidney metabolism may contribute to these differing outcomes. In adults with chronic kidney disease, increased plasma levels of TCA cycle metabolites positively associated with male sex, diabetes and all-cause mortality and negatively associated with
-
Clonal haematopoiesis and AKI Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-26 Susan J. Allison
Clonal haematopoiesis of indeterminate potential (CHIP) arises from the clonal expansion of a mutated haematopoietic stem cell. CHIP affects 10–20% of individuals aged ≥65 years and is associated with increased mortality, although only a small proportion of patients with CHIP progress to overt haematological cancer. Now, Caitlyn Vlasschaert and colleagues demonstrate that CHIP is associated with the
-
Switching off SOX9 for epithelial recovery after AKI Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-26 Monica Wang
In acute kidney injury (AKI), dysregulated tissue regeneration can promote fibrosis and chronic kidney disease. Sustained SOX9 expression after AKI is a key promoter of fibrosis, according to a new study by Sanjeev Kumar and colleagues. Epigenetic analyses suggest that cells with persistent SOX9 expression have a progenitor cell-like phenotype with patterns of chromatin reorganization that are associated
-
Drug stewardship in chronic kidney disease to achieve effective and safe medication use Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-15 Rasheeda K. Hall, Rümeyza Kazancıoğlu, Teerawat Thanachayanont, Germaine Wong, Dharshana Sabanayagam, Marisa Battistella, Sofia B. Ahmed, Lesley A. Inker, Erin F. Barreto, Edouard L. Fu, Catherine M. Clase, Juan J. Carrero
-
Role of biophysics and mechanobiology in podocyte physiology Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-05 Jonathan Haydak, Evren U. Azeloglu
-
Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-05 Djalila Mekahli, Roman-Ulrich Müller, Matko Marlais, Tanja Wlodkowski, Stefanie Haeberle, Marta López de Argumedo, Carsten Bergmann, Luc Breysem, Carla Fladrowski, Elizabeth P. Henske, Peter Janssens, François Jouret, John Christopher Kingswood, Jean-Baptiste Lattouf, Marc Lilien, Geert Maleux, Micaela Rozenberg, Stefan Siemer, Olivier Devuyst, Franz Schaefer, David J. Kwiatkowski, Olivier Rouvière
-
Innovating dialysis through computational modelling of hollow-fibre haemodialysers Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-03-04 Ruhit Sinha, Michael V. Rocco, Pirouz Daeihagh, Anne E. Staples
Haemodialyser technology has not advanced much in decades, despite its unresolved shortcomings. Sophisticated new computational tools such as high-fidelity surrogate in silico dialyser models could reduce the time and expense of exploring alternative designs, dialysis dose and operating conditions compared with the current gold standard in vitro studies.
-
Long-term health outcomes associated with hydration status Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-26 Natalia I. Dmitrieva, Manfred Boehm, Paul H. Yancey, Sofia Enhörning
-
The renal glucagon receptor is essential to kidney metabolic and homeostatic functions Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-29 Ellen F. Carney
Kidney glucagon receptors (GCGRs) are expressed along the nephron and downregulated in chronic kidney disease (CKD); however, their physiological functions are not well understood. A study by Philipp Scherer and colleagues provides insights into the roles of GCGRs in normal kidney function and in disease development. The researchers report that adult mice with constitutive or inducible kidney-specific
-
A CAAR NK cell approach to eliminate pathogenic autoantibody-secreting cells Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-28 Ellen F. Carney
Binding of autoantibodies to autoantigens expressed on podocytes causes membranous nephropathy. New findings suggest that chimeric autoantibody receptor (CAAR) natural killer (NK) cells could be used to eliminate pathogenic autoantibody-producing cells in this disease. The researchers conclude that CAAR NK and T cells can eliminate antibody-secreting target cells in an antigen-specific manner, demonstrating
-
Physiological principles underlying the kidney targeting of renal nanomedicines Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-26 Yingyu Huang, Xuhui Ning, Samira Ahrari, Qi Cai, Nilum Rajora, Ramesh Saxena, Mengxiao Yu, Jie Zheng
-
Organ trafficking — a continuing challenge Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-26 Thomas F. Mueller, Sanjay Nagral
Global inequities and inequalities, human and health-care crises, transplantation successes in the face of limited organ availability, and desperate donors and recipients underlie the backstory of organ trafficking, namely the exploitation of the most vulnerable. Despite the framework set out by the Declaration of Istanbul for the ethical donation and transplantation of organs, organ trafficking remains
-
Pericyte–stem cell crosstalk in ccRCC Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-26 Susan J. Allison
The cells that surround tumours can influence tumour growth and response to therapy. In new research, ChuanJie Zhang and colleagues report the identification of a subset of pericytes that sustain the proliferation of cancer stem cells (CSCs) in clear cell renal cell carcinoma (ccRCC) and promote tumour resistance to tyrosine kinase inhibitors (TKIs). PDGFRβ+GPR91+ pericytes, identified by single-cell
-
Sirtuins in kidney health and disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-06 Luca Perico, Giuseppe Remuzzi, Ariela Benigni
-
Macrophages clean out the tubules Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-02-01 Monica Wang
Urine supersaturation can lead to intraluminal accumulation of mineral crystals and kidney stone formation. A study by Xiao Z. Shen and colleagues now shows how juxtatubular macrophages keep these particles in check.
-
Design of a renal-sparing antifungal Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-30 Susan J. Allison
AmB kills fungi through the formation of large sponge-like aggregates that remove ergosterol from the cell membrane of fungi. However, Arun Maji and colleagues found that as well as removing ergosterol, AmB also removes cholesterol — a sterol that demonstrates similarities to ergosterol and is essential for normal functioning of the cell membrane — from the membranes of kidney cells. A series of investigations
-
Effects of SGLT2 inhibitors on the metabolic environment and uraemic toxins Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-30 Ellen F. Carney
Sodium–glucose co-transporter 2 (SGLT2) inhibitors have kidney and cardiovascular protective effects in individuals with and without diabetes. A multi-omics study provides insights into the mechanisms.
-
A united vision for cardiovascular–kidney–metabolic health Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-29 Susan E. Quaggin, Benjamin Magod
Improved understanding of the interrelated nature of cardiovascular, kidney and metabolic (CKM) health, the development of novel risk prediction equations, and the availability of powerful new therapies provide an opportunity to change the course of CKM health. Achieving such change at a population level will require additional advances to deliver equitable interdisciplinary care.
-
The multifaceted links between hearing loss and chronic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-29 Dina Greenberg, Norman D. Rosenblum, Marcello Tonelli
-
The changing landscape of HIV-associated kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-25 Nina E. Diana, Saraladevi Naicker
-
Amplifying the voices of patients with kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-22 Miranda Scanlon
All patients with kidney disease have the right to have a say in their own clinical care, the provision of health services and research into kidney disease. Patient empowerment and advocacy, especially for those whose views are seldom heard, can be enhanced by working together in communities.
-
Metabolic alterations in hereditary and sporadic renal cell carcinoma Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-22 Nathan J. Coffey, M. Celeste Simon
-
Health policy for universal, sustainable and equitable kidney care Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-18 Ricardo Silvariño, Laura Solá
Treatment of chronic kidney disease requires a comprehensive approach including universal access to early diagnosis and to medications that can slow disease progression. Such equitable access is not only an ethical requirement but can also reduce the financial and human costs of advancing kidney and cardiovascular disease.
-
Overcoming barriers to deliver high quality kidney care Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-11 Adeera Levin
Overcoming barriers to deliver high-quality care requires an assessment of the contribution of each barrier within a local context. Tools to identify early disease, knowledge of best therapies, access to care providers and medications, and an accountable and integrated health-care system are essential elements of quality care. Education of patients, providers and policy makers in conjunction with advocacy
-
Expanding the global nephrology workforce Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-10 Ikechi G. Okpechi, Somkanya Tungsanga, Anukul Ghimire, David W. Johnson, Aminu K. Bello
-
Vascular damage in systemic lupus erythematosus Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-03 William G. Ambler, Mariana J. Kaplan
-
Translating B cell immunology to the treatment of antibody-mediated allograft rejection Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-02 Peter S. Heeger, Maria Carrera Haro, Stanley Jordan
-
New and emerging therapies for diabetic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2024-01-02 Ricardo Correa-Rotter, Louise J. Maple-Brown, Rakesh Sahay, Katherine R. Tuttle, Ifeoma I. Ulasi
The theme of World Kidney Day 2024 is “kidney health for all — advancing equitable access to care and optimal medication practice”. To mark this event, Nature Reviews Nephrology invited five researchers from different geographical regions worldwide to discuss the impact of new and emerging therapies for diabetic kidney disease on patient care as well as the barriers that must be overcome to ensure
-
Single-cell genomics sheds light on kidney tissue immunity Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-21 Andrew P. Stewart, Menna R. Clatworthy
-
Reaping the rewards of mechanistic discovery in glomerular disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-20 Arpita Joshi, Laura H. Mariani
-
New evidence of the impact of mitochondria on kidney health and disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-14 Thomas Verissimo, Sophie de Seigneux
-
The dawn of multimodal artificial intelligence in nephrology Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-14 Benjamin Shickel, Azra Bihorac
-
Progress towards improving blood pressure control Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-06 Kate M. Denton
-
Targeted identification of risk and treatment of diabetic kidney disease Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-12-01 Sarah J. Glastras, Carol A. Pollock
Basic discovery and clinical trials in diabetic kidney disease (DKD) have continued to be reported in 2023 despite the disruption of research activity by COVID-19 in recent years. Advances in clinical trials and emerging ways to diagnose, monitor and treat DKD dominate the current literature.
-
Consideration of sex differences is necessary to achieve health equity Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-30
Improved understanding of the impact of sex and gender-related factors on human health and disease and the inclusion of people of all genders in research studies is necessary to reduce health inequities and enable a more personalized approach to patient care.
-
Renoprotective effects of sparsentan: clinical trial evidence in IgA nephropathy and FSGS Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-27 Monica Wang
In early 2023, the dual endothelin–angiotensin receptor antagonist sparsentan became the first non-immunosuppressive therapy to be approved by the US Food and Drug Administration for the treatment of IgA nephropathy (IgAN), on the basis of data that showed a reduction in proteinuria. Two new clinical trials presented at ASN Kidney Week 2023 further support the renoprotective potential of this therapy
-
Targeting APRIL to slow progression of IgA nephropathy Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-27 Monica Wang
TNF family ligands such as a proliferation-inducing ligand (APRIL) promote B cell expansion and survival. New clinical trial data presented at ASN Kidney Week 2023 suggest that targeting APRIL might be therapeutic in IgA nephropathy (IgAN).
-
Author Correction: The immunoregulatory roles of non-haematopoietic cells in the kidney. Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-23 George C Tsokos,Afroditi Boulougoura,Vivek Kasinath,Yushiro Endo,Reza Abdi,Hao Li
-
Mechanisms and consequences of sex differences in immune responses Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-22 Shannon E. Dunn, Whitney A. Perry, Sabra L. Klein
-
Differences in the epidemiology, management and outcomes of kidney disease in men and women Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-20 Nicholas C. Chesnaye, Juan Jesus Carrero, Manfred Hecking, Kitty J. Jager
-
The immunoregulatory roles of non-haematopoietic cells in the kidney Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-20 George C. Tsokos, Afroditi Boulougoura, Vivek Kasinath, Ushiro Endo, Reza Abdi, Hao Li
-
Kidney xenotransplantation edges closer to the clinic Nat. Rev. Nephrol. (IF 41.5) Pub Date : 2023-11-16 Eckhard Wolf, Bruno Reichart